769-24-4

Basic information

• Product Name: 1-PiperidineethanaMine, 2,6-diMethyl-
• Synonyms: 1-PiperidineethanaMine, 2,6-diMethyl-;2-(2,6-dimethylpiperidin-1-yl)ethan-1-amine
• CAS NO: 769-24-4
• Molecular Formula: C₉H₂₀N₂
• Molecular Weight: 156.2685
• Mol File: 769-24-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-PiperidineethanaMine, 2,6-diMethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PiperidineethanaMine, 2,6-diMethyl-(769-24-4)
• EPA Substance Registry System: 1-PiperidineethanaMine, 2,6-diMethyl-(769-24-4)

Safety Data

• Hazardous Substances Data: 769-24-4(Hazardous Substances Data)

Usage

Physical state

Clear, colorless liquid

Odor

Strong amine odor

Usage

Intermediate in the synthesis of pharmaceuticals and organic compounds

Application

Catalyst and corrosion inhibitor

Industrial use

Production of rubber and plastics, cleaning products, and fragrances

Safety precaution

Can be harmful if it comes into contact with the skin or if inhaled

Upstream product

• 825-28-5 (2,6-dimethyl-1-piperidinyl)acetonitrile 
• 504-03-0 2.6-dimethylpiperidine 

Downstream Products

• 88981-74-2 cis-N-[2-(2,6-dimethyl-1-piperidinyl)ethyl]-2-oxo-4-phenyl-1-pyrrolidineacetamide 

Relevant articles and documents

Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: The role of extravascular transport

Pharmacokinetic/pharmacodynamic (PK/PD) modeling has shown the antitumor activity of tirapazamine (TPZ), a bioreductive hypoxia-selective cytotoxin, to be limited by poor penetration through hypoxic tumor tissue. We have prepared a series of 1,2,4-benzotr

Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use

Aminothiazole compounds with mono-/di-substituted benzamide are represented by the Formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.

N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position

Novel pyrrolidine, piperidine and homopiperidinecarboxamide and thiocarboxamide compounds having the formula: STR1 wherein X is --S--, --S(O)-- or --S(O)2 --; A is a loweralkalene chain and A1 and A2 are alkalene chains when p and d are one; R, R1 and R2 are hydrogen, loweralkyl, phenyl cycloalkyl or phenylalkyl and R1 and R2 may form a heterocyclic residue with the adjacent nitrogen atom; Q is a selected aromatic radical, and the pharmaceutically acceptable acid addition salts useful as cardiac antiarrhythmia agents are disclosed. Novel chemical intermediates, unsubstituted on pyrrolidine, piperidine and homopiperidine nitrogen but with --(A2)p --X--(A2)d --Q side chain are also disclosed.